Lataa...
Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. H...
Tallennettuna:
| Julkaisussa: | Diabetes Metab Syndr Obes |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5473486/ https://ncbi.nlm.nih.gov/pubmed/28652790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S132537 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|